ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative6.2 M5.23 M3.63 M4.05 M3.77 M16.68 MRicerca e sviluppo9.37 M4.3 M3.66 M2.83 M6.71 M17.5 MReddito operativo-15.57 M-9.54 M-7.29 M-6.87 M-78.56 M-102.27 MProventi non operativi, Totale563 K393 K325 K263 K255 K1.24 MOneri finanziari, al netto degli interessi capitalizzati——————Proventi non operativi, esclusi gli oneri finanziari000000Entrate/uscite straordinarie563 K393 K325 K263 K255 K1.24 MUtile al lordo delle imposte-96.94 M-9.14 M-6.97 M-6.61 M-105.61 M-128.33 MQuota di utile——————Imposte————-2.67 M—Interessi di minoranza——————Altri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate-15 M-9.14 M-6.97 M-6.61 M-82.89 M-105.61 MAttività cessate——————Utile netto-15 M-9.14 M-6.97 M-6.61 M-82.89 M-105.61 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari-15 M-9.14 M-6.97 M-6.61 M-82.89 M-105.61 MUtile base per azione (EPS base)-3.84-2.3-1.8-1.68-18.92-24.7Utile diluito per azione (EPS diluito)-3.84-2.3-1.8-1.68-18.92-24.7Numero medio di azioni ordinarie in circolazione3.85 M3.9 M3.91 M3.94 M4.28 M16.03 MAzioni diluite in circolazione3.85 M3.9 M3.91 M3.94 M4.28 M16.03 MEBITDA-15.27 M—————EBIT-15.57 M—————Costo del fatturato——————Altri costi del venduto——————Ammortamento e svalutazione (liquidità)301 K178 K73 K130 K262 K643 K
LeonaBio Inc
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.